Skip to content

MoonLake Immunotherapeutics MLTX Operating Lease Liabilities

Operating Lease Liabilities at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$1.13M+69.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$11.49M-15.6%
Opko Health logo
Opko HealthOPK
$35.64M-7.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$60.63M-22.8%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$2.32M-58.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$65.59M-7.9%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's operating lease liabilities?
MoonLake Immunotherapeutics (MLTX) reported operating lease liabilities of $865K in Q1 2026.
How has MoonLake Immunotherapeutics's operating lease liabilities changed year-over-year?
MoonLake Immunotherapeutics's operating lease liabilities decreased by 24.3% year-over-year, from $1.14M to $865K.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.